Sands Capital Life Sciences Pulse Fund II Reports Acquisition of Inhibikase Therapeutics Common Shares
Sands Capital Life Sciences Pulse Fund II, L.P. has acquired common shares of Inhibikase Therapeutics Inc. (IKT), as reported in a recent regulatory filing. The filing was submitted by Sands Capital Life Sciences Pulse Fund II, L.P. and other beneficial owners. This information was originally published by Inhibikase Therapeutics Inc. via the EDGAR system of the U.S. Securities and Exchange Commission.
Sands Capital Life Sciences Pulse Fund II, L.P. has reported the acquisition of common shares of Inhibikase Therapeutics Inc. (IKT), according to a recent regulatory filing. The filing was submitted by Sands Capital Life Sciences Pulse Fund II, L.P. along with other reporting beneficial owners. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibikase Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001875620-25-000025), on November 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
